Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. reports developments in clinical-stage immunology therapeutics and immune-modulating biologics. Company updates center on its Immuno-STAT platform, the autoimmune and inflammatory disease candidate CUE-401, a clinical-stage dual-mechanism anti-IgE antibody for allergic diseases, and collaboration activity involving B cell depletion programs such as CUE-501.
Recurring news also covers leadership changes, inducement equity awards, shareholder-approved capital actions, research presentations, milestone payments, licensing activity, and other corporate matters tied to Cue Biopharma's Nasdaq-listed common stock and clinical-stage operating model.
Cue Biopharma (Nasdaq:CUE) reported Q1 2026 collaboration revenue of $5.7 million, up from $0.4 million in Q1 2025, and a net loss of $5.2 million, reduced from $12.3 million. R&D expenses fell to $6.9 million, G&A held at $4.2 million.
The company licensed CUE-221, a Phase 2 anti-IgE asset for allergic disease, and advanced CUE-401, an autoimmune candidate. Liquidity was strengthened by a $30 million private placement and a $7.5 million milestone from Boehringer Ingelheim. Shao-Lee Lin, M.D., Ph.D., was appointed President and CEO.
Cue Biopharma (Nasdaq: CUE) announced inducement equity awards on May 3, 2026, to seven new employees including newly appointed president and CEO Shao-Lee Lin, M.D., Ph.D. Grants include a non-statutory option for 655,074 shares and 327,537 RSUs for Dr. Lin, plus aggregate option grants of 518,599 shares and 327,534 RSUs to six other new employees. Options use an exercise price of $30.42 per share (May 1, 2026 close). Dr. Lin’s option vests monthly over four years; her RSUs were fully vested on grant. Other employees’ options vest quarterly over four years; their RSUs vested on grant.
Cue Biopharma (NASDAQ: CUE) announced a private placement expected to raise approximately $30 million in gross proceeds via pre-funded warrants and accompanying warrants. The PIPE is expected to close on or about May 4, 2026, subject to customary conditions and stockholder approval.
Proceeds are intended to advance the clinical pipeline, including acquiring and developing Ascendant-221, and for working capital and general corporate purposes. Newbridge Securities is placement agent; resale registration will be filed with the SEC.
Cue Biopharma (Nasdaq: CUE) entered an exclusive license agreement for Ascendant-221, a Phase 2 anti-IgE antibody, gaining global rights excluding mainland China, Hong Kong, Macau and Taiwan.
Deal consideration includes a $15 million upfront fee, up to $676.5 million in milestone payments and tiered royalties. Ascendant-221 Phase 2 results from a China study are expected in 2H 2026; Cue plans a global Phase 2b in food allergy after data review.
Cue Biopharma (Nasdaq: CUE) appointed Shao-Lee Lin, M.D., Ph.D., as CEO, President and board director effective April 30, 2026.
Dr. Lin brings 25+ years of leadership, previously founded and led a Nasdaq company, raised over $1 billion, and guided a $2+ billion IPO valuation. Cue highlighted advancement of CUE-401 to Phase 1 and an added ongoing Phase 2 program targeting allergic disease with a potential near-term inflection in 2H2026.
Cue Biopharma (Nasdaq: CUE) will implement a 1-for-30 reverse stock split effective 5:00 p.m. ET on April 23, 2026, with split-adjusted trading expected when markets open April 24, 2026 under ticker CUE and new CUSIP 22978P205.
The split reduces outstanding shares from ~97.7 million to ~3.3 million and is intended to help the company regain compliance with Nasdaq Capital Market minimum bid price requirements; fractional shares will be paid in cash and equity awards will be adjusted proportionately.
Cue Biopharma (Nasdaq: CUE) will present new preclinical data on lead candidate CUE-401 at IMMUNOLOGY2026 in Boston, April 15-19, 2026. The poster describes a bifunctional TGF-beta/IL-2 fusion that promotes antigen-specific FOXP3+ iTreg expansion, supporting potential to restore immune homeostasis.
Cue Biopharma (Nasdaq: CUE) will receive a $7.5 million preclinical milestone payment from its collaboration and license agreement with Boehringer Ingelheim after selection and approval of the first compound for lead optimization. The company expects the payment in May 2026. The multi-year collaboration could yield up to $337.5 million in additional milestone payments plus royalties and allows expansion into B cell-targeting bispecifics. Cue is advancing its lead autoimmune asset, CUE-401, toward the clinic while Boehringer Ingelheim will further develop CUE-501 under the agreement.
Cue Biopharma (Nasdaq: CUE) appointed Lucinda Warren as interim president and chief executive officer, effective March 27, 2026, after Usman Azam stepped down effective March 26, 2026. The board credited Ms. Warren with recent deal execution, including recovery of CUE-401 rights and collaborations with Boehringer Ingelheim and ImmunoScape.
Ms. Warren said she will focus on advancing CUE-401 into the clinic by the second half of 2026; she has 30+ years of global pharma and biotech experience and prior business development leadership at Johnson & Johnson.
Cue Biopharma (Nasdaq: CUE) will host a virtual R&D Day on April 7, 2026 at 10:00 AM EDT to present research on its lead asset, CUE-401, aimed at regulating proinflammatory mechanisms and promoting Treg differentiation for autoimmune and inflammatory diseases.
Key Opinion Leaders Richard DiPaolo, PhD, and Jonathan Kay, MD, will join company management for presentations, followed by a live Q&A. A live and archived webcast will be available on the company website and will be archived for 30 days.